The Estée Lauder Companies Inc. (NYSE: EL) \& COTY INC. (NYSE: COTY)

Drew Lojewski
April 2022



COMPANIES


BEAUTY, LIBERATED

## I. Introduction

II. Company Background
III. Acquisition Drivers
IV. Model, Valuation, \& Financials
I. INTRODUCTION


## II. Company Background

## BUSINESS DESCRIPTION

Estée Lauder engages in the manufacture and sale of skin care, fragrance, makeup, and hair care products

- The company operates in 5 business segments:
- Skin Care: Includes moisturizers, serums, cleansers, exfoliators, acne care, facial mask, sun care products, etc.
- Makeup: Includes lipsticks, mascaras, foundations, etc.
- Fragrance: Includes sprays, colognes, candles, etc.
- Hair Care: Includes shampoos, conditioners, etc.
- Other: Includes ancillary products and services
- As of FY2020, the Company operates $\sim 1,600.00$ stores


## Revenue by Geographic Segment



| (\$ in millions) | 2021A |  | 2020A |  | 2019A |  | 2018A |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Sales | \$ | 16,251.00 | \$ | 14,259.00 | \$ | 14,835.00 | \$ | 13,683.00 |
| Growth |  | 13.97\% |  | -3.88\% |  | 8.42\% |  | 15.72\% |
| Total Expense | \$ | 13,118.00 | \$ | 12,262.00 | \$ | 12,320.00 | \$ | 11,250.00 |
| Margin |  | 80.72\% |  | 85.99\% |  | 83.05\% |  | 82.22\% |
| Operating Income | \$ | 3,133.00 | \$ | 1,997.00 | \$ | 2,515.00 | \$ | 2,433.00 |
| Margin |  | 19.28\% |  | 14.01\% |  | 16.95\% |  | 17.78\% |
| Net Income | \$ | 2,870.00 | \$ | 684.00 | \$ | 1,785.00 | \$ | 1,108.00 |
| Growth |  | 319.59\% |  | -61.68\% |  | 61.10\% |  | -11.29\% |

## BUSINESS DESCRIPTION

Coty engages in the manufacture, distribution, marketing, and sale of branded beauty products

- The company operates in 3 business segments:
- Fragrances: Includes products that contain a combination of chemicals to give its unique scent
- Color Cosmetics: Includes beauty products designed to alter one's appearance, such as make-up and nail polish
- Body Care \& Other: Includes products designed for use on the skin, such as lotions, creams, and moisturizers
- The Company makes prestige and mass beauty products for $\sim 39.00$ brands organically and through licensing deals


## Revenue by Geographic Segment



## Revenue By Business Segment



Key Figures

| (\$ in millions) | 2021A |  | 2020A |  | 2019A |  | 2018A |  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Sales | $\$$ | $4,628.90$ | $\$$ | $4,717.20$ | $\$$ | $6,287.90$ | $\$$ | $9,398.80$ |
| $\quad$ Growth |  | $-1.87 \%$ | $-24.98 \%$ |  | $-33.10 \%$ | $22.89 \%$ |  |  |
| Total Expense | $\$$ | $4,476.20$ | $\$$ | $5,104.00$ | $\$$ | $6,043.70$ | $\$$ | $8,760.30$ |
| $\quad$ Margin |  | $96.70 \%$ | $108.20 \%$ |  | $96.12 \%$ | $93.21 \%$ |  |  |
| Operating Income | $\$$ | 152.70 | $\$$ | $(386.80)$ | $\$$ | 244.20 | $\$$ | 638.50 |
| $\quad$ Margin |  | $3.30 \%$ | $-8.20 \%$ |  | $3.88 \%$ | $6.79 \%$ |  |  |
| Net Income | $\$$ | $(64.00)$ | $\$$ | $(1,093.90)$ | $\$$ | $(3,905.20)$ | $\$$ | $(168.80)$ |
| $\quad$ Growth |  | $94.15 \%$ | $71.99 \%$ | $-2213.51 \%$ | $60.02 \%$ |  |  |  |

## INDUSTRY OVERVIEW

- Firms in the Cosmetic and Beauty Product industry generally engage in the development, marketing, manufacturing, sale, and distribution of personal care and beauty-related products, including perfumes, makeup items, hair products, creams, lotions, and skin care products
- The Cosmetic and Beauty Products industry is part of the Personal Products subsector, the least defensive sector in Consumer Staples
- The industry has underperformed as the COVID-19 pandemic began, especially for luxury products linked to travel and leisure activity
- Some key trends for the industry include a shift to more eco-friendly products and more product offerings for diverse populations
- Eco-friendly personal products include natural ingredients from renewable raw materials, such as natural oils and agricultural plants
- The total value of M\&A deals in the subsector dropped $\sim 80.23 \%$ in CY2020 to $\sim \$ 6.90$ bn, but increased to $\sim \$ 21.80$ bn in CY2021

| COMPANY | SIZE (BN) |  | Estée Lauder engages in the manufacture of skin care, <br> fragrance, hair care, and makeup products. It sells products <br> under various brand names, including Clinique, Estée Lauder, <br> and MAC, and also operates over 1,000.00 independent stores |
| :--- | :--- | :--- | :--- |
| Coty manufactures, distributes, and sells branded prestige and |  |  |  |

## The Estée Lauder Companies Inc. Nominal Performance and Key Events



## COTY INC. Nominal Performance and Key Events



III. AcQuisition Drivers

## Exposure to Diverse Supply Chain Pipelines

A merger between Estée Lauder and COTY would bring increased specialized resources to produce product

- COTY currently manufactures $\sim 85.00 \%$ of its product, and discussed plans of outsourcing more of its supply chain to other businesses to further optimize operations
- EL has reported COGS of $\sim 19.00 \%$ of revenue in FY2021, compared to $\sim 31.00 \%$ of revenue for COTY
- Estée Lauder's new R\&D and manufacturing facilities can complement COTY's lack of exposure to international markets and catalyze slowing EMEA and APAC sales


## Number of Facilities by Region

|  | Americas |  |  |  | EMEA |  |  |  | APAC |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | EL |  | COTY |  | EL |  | COTY |  | EL |  | COTY |  |
|  | 0 | L | O | L | O | L | O | L | 0 | L | O | L |
| Mfg./Dist. | 3 | 11 | 3 | 0 | 5 | 10 | 5 | 1 | 1* | 2 | 1 | 0 |
| R\&D | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 1* | 2 | 0 | 0 |
| Corporate | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 |
| Total | 4 | 14 | 3 | 2 | 5 | 10 | 5 | 3 | 2 | 4 | 1 | 1 |
| Total O\&L | 18 |  | 5 |  | 15 |  | 8 |  | 6 |  | 2 |  |

Key: $O=O$ wned, $L=$ Leased
Source: Company Filings, *EL Tokyo Mfg. and Shanghai R\&D Facilities in Construction

## Margin and Structure Synergies

Estée Lauder can provide COTY with the expertise to improve its margins, therefore boosting operating profits

- COTY has stressed the importance of its ability to stabilize and improve profitability through the Transformation Plan
- The program highlights the Company's vision of enhancing margin growth and overall cost controls
- Estée Lauder announced the Post-COVID Business Alliance Program (PCBA) in August CY2020
- The program is designed to further enhance efficiencies and focus on growing areas of the prestige beauty market

Company Gross Margins (Last 12 Quarters)


Source: Bloomberg

## Prestige/Mass Beauty Growth Opportunity

COTY's prestige and mass beauty exposure could catalyze Estée Lauder's growth in multiple markets

- COTY derives $\sim 63.87 \%$ of revenue from Prestige Beauty products, unlike Estée Lauder's focus on Mass Beauty
- The target age demographic for Estée Lauder is women aged $\sim 35.00-\sim 55.00$, unlike $\sim 25.00-\sim 35.00$ for COTY
- Estée Lauder has increasingly focused sales in the EMEA and APAC regions, compared to the Americas for COTY
- COTY maintains $\sim 25.00$ brand licenses, including popular brands used for Mass and Prestige Beauty products
Prestige vs. Mass Beauty Per Capita Spending Growth (5-Yr CaGR)



## Increased Efficiencies of Point of Sale

Estée Lauder can use COTY's eCommerce and independent store model to improve operating costs

- Although both Companies earn revenue from eCommerce sales, COTY does not operate free-standing retail locations
- Estée Lauder plans to close locations to improve efficiencies
- The Company projects a reduction SG\&A expenses of $\sim \$ 400.00 \mathrm{MM}-\sim \$ 500.00 \mathrm{MM}$ within $\sim 2.00$ years
- This complements Estée Lauder's PCBA Program, stressing decreased physical store expenses, while still growing sales in both eCommerce and brick-and-border locations

Revenue Share Among Geographic Regions


## IV. Model, Valuation, \& Financials

Income Statement for The Estée Lauder Companies, Inc. (MM except per share items)

| Year (FY) | Historical |  |  | Projected |  |  |  |  | 5-yr CAGR |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2019A | 2020A | 2021A | 2022E | 2023E | 2024E | 2025E | 2026E |  |
| Revenue | 14,835 | 14,259 | 16,251 | 18,567 | 20,433 | 22,272 | 24,053 | 25,857 | 3.4\% |
| \% growth | 8\% | -4\% | 14\% | 14\% | 10\% | 9\% | 8\% | 8\% |  |
| COGS | $(2,830)$ | $(2,931)$ | $(3,167)$ | $(3,342)$ | $(3,657)$ | $(3,964)$ | $(4,257)$ | $(4,577)$ |  |
| \% of Revenue | 19\% | 21\% | 19\% | 18\% | 18\% | 18\% | 18\% | 18\% |  |
| Gross Profit | 12,005 | 11,328 | 13,084 | 15,225 | 16,775 | 18,307 | 19,796 | 21,281 | 3.4\% |
| Gross Margin | 81\% | 79\% | 81\% | 82\% | 82\% | 82\% | 82\% | 82\% |  |
| SG\&A | $(8,731)$ | $(8,492)$ | $(9,057)$ | $(10,325)$ | $(11,099)$ | $(11,932)$ | $(12,827)$ | $(13,789)$ |  |
| R\&D | (202) | (228) | (243) | (255) | (269) | (282) | (297) | (311) |  |
| D\&A | (557) | (611) | (651) | (744) | (819) | (892) | (964) | $(1,036)$ |  |
| EBIT(Operating Income) | 2,515 | 1,997 | 3,133 | 3,901 | 4,588 | 5,201 | 5,709 | 6,145 | 4.6\% |
| EBIT Margin | 17\% | 14\% | 19\% | 21\% | 22\% | 23\% | 24\% | 24\% |  |
| Interest Income (Expense) | 41 | (22) | 679 | 101 | 119 | 139 | 161 | 186 |  |
| Other Expenses | (249) | (929) | (481) | (481) | (481) | (481) | (481) | (481) |  |
| Pre-Tax Income | 2,307 | 1,046 | 3,331 | 3,521 | 4,226 | 4,859 | 5,389 | 5,850 |  |
| Tax Expense | (513) | (350) | (456) | (556) | (679) | (828) | $(1,010)$ | $(1,232)$ |  |
| Tax Rate | 22\% | 33\% | 14\% | 22\% | 22\% | 22\% | 22\% | 22\% |  |
| Net Income Attributable to EL | 1,794 | 696 | 2,875 | 2,965 | 3,548 | 4,031 | 4,379 | 4,618 | 4.5\% |
| EBITDA | 3,072 | 2,608 | 3,784 | 4,645 | 5,407 | 6,093 | 6,673 | 7,181 |  |
| EBITD A Margin | 21\% | 18\% | 23\% | 25\% | 26\% | 27\% | 28\% | 28\% |  |
| Basic Earnings Per Share | \$4.94 | \$1.93 | \$7.92 | \$8.27 | \$9.89 | \$11.24 | \$12.21 | \$12.87 |  |
| Diluted Earnings Per Share | \$4.84 | \$1.90 | \$7.81 | \$8.21 | \$9.82 | \$11.16 | \$12.12 | \$12.78 |  |
| Basic Shares Outstanding | 364 | 361 | 363 | 359 | 359 | 359 | 359 | 359 |  |
| Diluted Shares Outstanding | 370 | 367 | 368 | 361 | 361 | 361 | 361 | 361 |  |


| Year (FY) | Historical |  |  | Projected |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2020A | 2020A | 2021A | 2022E | 2023E | 2024E | 2025E | 2026E |
| Assets |  |  |  |  |  |  |  |  |
| Current Assets |  |  |  |  |  |  |  |  |
| Cash \& Cash Equivalents | 2,987 | 5,022 | 4,958 | 5,781 | 6,692 | 7,884 | 9,218 | 10,458 |
| Receivables | 1,831 | 1,194 | 1,702 | 1,940 | 2,135 | 2,327 | 2,514 | 2,702 |
| Inventories | 2,006 | 2,062 | 2,505 | 2,643 | 2,893 | 3,136 | 3,368 | 3,620 |
| Other Current Assets | 388 | 614 | 603 | 712 | 840 | 991 | 1,169 | 1,380 |
| Total Current Assets | 7,212 | 8,892 | 9,768 | 11,076 | 12,560 | 14,338 | 16,268 | 18,160 |
| Non-Current Assets |  |  |  |  |  |  |  |  |
| PP\&E | 4,831 | 7,416 | 7,808 | 7,860 | 8,037 | 8,389 | 8,981 | 9,889 |
| Accumulated Depreciation | $(2,763)$ | $(3,079)$ | $(3,338)$ | $(3,472)$ | $(3,576)$ | $(3,647)$ | $(3,684)$ | $(3,702)$ |
| Long Term Investments | 177 | ( |  |  | ) | , | - |  |
| Goodwill | 1,868 | 1,401 | 2,616 | 3,035 | 3,520 | 4,083 | 4,737 | 5,494 |
| Intangibles | 1,203 | 2,338 | 4,095 | 4,750 | 5,510 | 6,392 | 7,415 | 8,601 |
| Deferred Tax Assets | 295 | 44 |  | 100 | 300 | 450 | 563 | 703 |
| Other Non-Current Assets | 333 | 769 | 1,022 | 1,186 | 1,328 | 1,474 | 1,621 | 1,783 |
| Total Non-Current | 5,944 | 8,889 | 12,203 | 13,459 | 15,120 | 17,141 | 19,632 | 22,769 |
| Total Assets | 13,156 | 17,781 | 21,971 | 24,535 | 27,679 | 31,479 | 35,900 | 40,928 |
| Liabilities |  |  |  |  |  |  |  |  |
| Current Liabilities |  |  |  |  |  |  |  |  |
| Accounts Payable | 1,490 | 1,177 | 1,692 | 1,786 | 1,954 | 2,118 | 2,275 | 2,445 |
| Current Maturities and Leases | 516 | 1,597 | 411 | 470 | 517 | 563 | 608 | 654 |
| Other Current Liabilities | 2,599 | 2,405 | 3,195 | 3,355 | 3,692 | 4,024 | 4,346 | 4,672 |
| Total Current Liabilities | 4,605 | 5,179 | 5,298 | 5,610 | 6,163 | 6,705 | 7,229 | 7,771 |
| Non-Current Liabilities |  |  |  |  |  |  |  |  |
| Long-Term Debt | 2,896 | 7,192 | 7,688 | 7,073 | 6,507 | 5,987 | 5,508 | 5,067 |
| Other Non-Current Liabilities | 1,244 | 1,448 | 2,037 | 2,327 | 2,561 | 2,792 | 3,015 | 3,241 |
| Total Non-Current Liabilities | 4,140 | 8,640 | 9,725 | 9,400 | 9,068 | 8,778 | 8,523 | 8,308 |
| Total Liabilities | 8,745 | 13,819 | 15,023 | 15,010 | 15,231 | 15,484 | 15,752 | 16,079 |
| Equity |  |  |  |  |  |  |  |  |
| Common Stock \& APIC | 4,409 | 4,796 | 5,341 | 5,341 | 5,341 | 5,341 | 5,341 | 5,341 |
| Retained Earnings | 9,984 | 10,134 | 12,244 | 15,830 | 20,004 | 24,701 | 29,719 | 34,980 |
| Accumulated Other Loss | $(10,007)$ | $(10,995)$ | $(11,528)$ | $(12,509)$ | $(13,759)$ | $(14,910)$ | $(15,774)$ | $(16,335)$ |
| Accumulated Minority Interest | 25 | 27 | 891 | 863 | 863 | 863 | 863 | 863 |
| Total Equity | 4,411 | 3,962 | 6,948 | 9,525 | 12,448 | 15,996 | 20,149 | 24,849 |
| Total Liabilities and Equities | 13,156 | 17,781 | 21,971 | 24,535 | 27,679 | 31,479 | 35,900 | 40,928 |



Income Statement for COTY INC. (MM except per share items)

| Year (FY) | Historical |  |  | Projected |  |  |  |  | 5-yr CAGR |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2019A | 2020A | 2021A | 2022E | 2023E | 2024E | 2025E | 2026E |  |
| Revenue | 8,649 | 4,717 | 4,629 | 5,289 | 5,685 | 6,083 | 6,448 | 6,771 | 2.5\% |
| \% growth | -8\% | -45\% | -2\% | 14\% | 8\% | 7\% | 6\% | 5\% |  |
| COGS | $(2,914)$ | $(1,389)$ | $(1,446)$ | $(1,534)$ | $(1,634)$ | $(1,734)$ | $(1,822)$ | $(1,896)$ |  |
| \% of Revenue | 34\% | 29\% | 31\% | 29\% | 29\% | 29\% | 28\% | 28\% |  |
| Gross Profit | 5,734 | 3,328 | 3,183 | 3,755 | 4,051 | 4,349 | 4,627 | 4,875 | 2.6\% |
| Gross Margin | 66\% | 71\% | 69\% | 71\% | 71\% | 72\% | 72\% | 72\% |  |
| SG\&A | $(4,239)$ | $(2,801)$ | $(2,267)$ | $(2,720)$ | $(2,992)$ | $(3,217)$ | $(3,377)$ | $(3,462)$ |  |
| R\&D | (163) | (93) | (97) | (104) | (112) | (120) | (129) | (139) |  |
| D\&A | (736) | (821) | (667) | (600) | (546) | (502) | (467) | (439) |  |
| EBIT(Operating Income) | 596 | (387) | 153 | 331 | 401 | 511 | 653 | 835 | 9.7\% |
| EBIT Margin | 7\% | -8\% | 3\% | 6\% | 7\% | 8\% | 10\% | 12\% |  |
| Interest Income (Expense) | (296) | (214) | (255) | (255) | (241) | (250) | (249) | (247) |  |
| Unusual Expenses | $(4,068)$ | (965) | (177) | (100) | (90) | (81) | (73) | (66) |  |
| Other Income (Expense) | (11) | 98 | 39 | 42 | 44 | 46 | 48 | 51 |  |
| Pre-Tax Income | $(3,778)$ | $(1,468)$ | (240) | 18 | 114 | 226 | 380 | 574 |  |
| Tax Expense | 9 | 378 | 172 | 200 | 231 | 268 | 311 | 361 |  |
| Tax Rate | $N / A$ | N/A | $N / A$ | 16\% | 16\% | 16\% | 16\% | 16\% |  |
| Minority Interest | (15) | (4) | 4 | (5) | (2) | (1) | (3) | (2) |  |
| Net Income Attributable to COTY | $(3,784)$ | $(1,094)$ | (64) | 213 | 344 | 493 | 689 | 933 | 15.9\% |
| EBITDA | 3,072 | 2,608 | 3,784 | 931 | 947 | 1,013 | 1,120 | 1,274 |  |
| EBITDA Margin | 36\% | 55\% | 82\% | 18\% | 17\% | 17\% | 17\% | 19\% |  |
| Basic Earnings Per Share | -\$5.04 | -\$1.44 | -\$0.08 | \$0.25 | \$0.41 | \$0.59 | \$0.82 | \$1.11 |  |
| Diluted Earnings Per Share | -\$5.04 | -\$1.44 | -\$0.08 | \$0.25 | \$0.40 | \$0.57 | \$0.80 | \$1.08 |  |
| Basic Shares Outstanding | 751 | 759 | 765 | 839 | 839 | 839 | 839 | 839 |  |
| Diluted Shares Outstanding | 751 | 759 | 765 | 865 | 865 | 865 | 865 | 865 |  |


| Balance Sheet for COTY INC. (MM) |
| :--- |
| Year (FY) |



## Unlevered Free Cash Flow for COTY INC. (MM)

| Year (FY) | Historicals |  |  | Projected |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2019A | 2020A | 2021A | 2022E | 2023E | 2024E | 2025E | 2026E |
| EBITDA | 596 | (387) | 153 | 331 | 401 | 511 | 653 | 835 |
| EBITDA Margin | 7\% | -8\% | 3\% | 6\% | 7\% | 8\% | 10\% | 12\% |
| Less DosA | (736.00) | (821.00) | (666.50) | (599.85) | (545.86) | (502.19) | (467.04) | (439.02) |
| EBIT | 596 | (387) | 153 | 331 | 401 | 511 | 653 | 835 |
| EBIT Margin | 7\% | -8\% | 3\% | 6\% | 7\% | 8\% | 10\% | 12\% |
| Tax Rate | N/A | N/A | N/A | 16\% | 16\% | 16\% | 16\% | 16\% |
| Plus D\&A | 736 | 821 | 667 | 600 | 546 | 502 | 467 | 439 |
| Less: Capital Expenditures | (427) | (267) | (174) | (226) | (294) | (382) | (497) | (646) |
| Less: Change in Net Working Capital | (205) | 2,910 | (632) | (21) | 323 | 669 | 963 | 1,276 |
| Unlevered Free Cash Flow (uFCF) | 701 | 3,077 | 13 | 405 | 639 | 871 | 1,038 | 1,203 |
| Present Value of uFCF | - | - | - | 374 | 544 | 684 | 752 | 804 |


| Assumptions: |  |  |
| :--- | ---: | ---: |
| Long-term Growth Rate | $2.50 \%$ | Assumption |
| WACC | $8.40 \%$ | FactSet |
| Cost of Debt | $4.69 \%$ | FactSet |
| Tax Rate | $16.00 \%$ | $10-\mathrm{Q}$ |
| Beta | 1.20 | Factset (5-Year Adjusted) |
|  |  |  |
| Implied Values (MM) |  | 20,898 |
| Terminal Value | 13,962 |  |
| Present Value of Terminal Value | $82 \%$ |  |
| \% Enterprise Value |  | 3,157 |
| Present Value of uFCF |  | $18 \%$ |
| \% Enterprise Value |  | 17,119 |
| Implied Enterprise Value |  | 10,436 |
| Implied Equity Value |  | 864.58 |
| Diluted Shares Outstanding |  |  |
|  |  | $\$ 12.07$ |
| Implied Share Price: |  |  |

(\$ in millions)

| Date | Target | Acquirer | Value | Equity Value | Payment Type | TV/Revenue | TV/EBIT | TV/EBITDA |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 5/16/2019 | Galderma Holding SA | Abhu Dhabi Investment Authority | \$10,200.00 | \$10,200.00 | Cash | 3.28x | 44.07x | 39.74x |
| 2/12/2019 | COTY INC. | JAB Holding Co. Sarl. | \$9,149.53 | \$1,750.43 | Cash | 1.81x | 16.87x | 12.90x |
| 5/22/2019 | Avon Products Inc. | Natura \& Co. Holding SA | \$4,110.45 | \$2,697.55 | Stock | 1.97x | 17.11x | 13.22x |
| 9/25/2017 | Carver Korea Co. Ltd. | Unilever NV | \$2,270.00 | \$2,270.00 | Cash | 3.28x | 44.07x | 39.74x |
| 7/11/2019 | Laboratoires Filorga Cosmetiques SAS | Colgate-Palmolive Co. | \$1,516.00 | \$1,516.00 | Cash | 3.28x | 44.07x | 39.74x |
| 1/29/2018 | Albea Sarl | PAI Partners SAS | \$1,518.00 | \$620.00 | Stock \& Debt | 3.28x | 44.07x | 39.74x |

(\$ in millions, except per share items)

| Transaction Assumptions |  |
| :---: | :---: |
| General information |  |
| Current date | 5/12/2022 |
| Acquirer |  |
| Name | The Estée Lauder Companies, Inc. |
| Ticker | EL |
| Latest filing date | 12/31/2021 |
| Filing type (10K or 10Q) | 10Q |
| Current share price | \$231.00 |
| Target |  |
| Name | COTY INC. |
| Ticker | COTY |
| Latest filing date | 12/31/2021 |
| Filing type (10K or 10Q) | 10Q |
| Current share price | \$6.31 |
| \% Offer premium | 20\% |
| Offer price per share | \$7.57 |
| Diluted shares outstanding (MM) | 864.6 |
| Offer value | 6,546.6 |
| Deal structure |  |
| \% Stock | 0\% |
| \% Cash | 100\% |
| Tax structure | Stock Sale |
| Acquirer shares issued in transaction | 0.00 |
| Nominal exchange ratio (offer price/ acq share price) | 0.03x |
| Actual exchange ratio (\% stock. x offer price/ acq share price) | 0.00x |
| Other assumptions |  |
| Deal fees as \% of offer value | 2.00\% |
| Deal fees | 130.93 |
| Assumed annual pretax cost synergies | 100.00 |
| The Estée Lauder Companies, Inc. Calendar Year Ending 2022 EBITDA | 4,736.00 |
| COTY INC. Calendar Year Ending 2022 EBITDA | 952.00 |
| Acquirer tax rate | 21.50\% |
| Target tax rate | 16.00\% |


| Transaction financing |  |
| :--- | ---: |
| \% Cash consideration financed with debt | $75 \%$ |
| $\%$ Cash consideration financed with excess cash | $25 \%$ |
| Acquirer new borrowing | 4909.973683 |
| Acquirer excess cash used | 1636.657894 |
| $\%$ of total acquirer cash balance | $33.01 \%$ |
| Treatment of target debt | Refinanced |
| Debt to be refinanced | 5425.2 |
| Total acquisition financing | 10335.17368 |
|  |  |
| Acquirer available cash | 4958.00 |
| Target debt outstanding | 5425.2 |
|  |  |
| Term of loan | 5 |
| Financing fees as \% of acquisition financing | 103.35 |
| Financing fees | 20.67 |
| Annual financing fee amortization | $4.0 \%$ |
| Interest rate on new debt | $1.0 \%$ |
| Interest earned on cash |  |


| (\$ in millions) |  |
| :---: | :---: |
| Sources \& Uses of Funds |  |
| Sources of Funds |  |
| New borrowing to acquire target | \$4,909.97 |
| New borrowing to refinance target debt | \$5,425.20 |
| Cash used to acquire target | \$1,636.66 |
| Value of stock issued to acquire target | \$0.00 |
| Cash for fees | \$234.28 |
| Total sources | \$12,206.116 |
| Uses of Funds |  |
| Stock to target | 0.00 |
| Cash to target | 6546.63 |
| Target debt refinanced | 5425.20 |
| Deal fees (advisory, legal, and accounting) | 130.93 |
| Financing fees (related to acq debt) | 103.35 |
| Total Uses | 12206.12 |
| Do sources equal uses? | Yes |


| Write-Ups and Purchase Price Allocation |  |
| :--- | ---: |
|  |  |
| Asset write-ups |  |
| Tangible assets | 772.7 |
| Book value of target PP\&E | $20 \%$ |
| \% Write-up | 154.5 |
| Asset write-up | 15 years |
| Useful life | 10.3 |
| Incremental depreciation expense | 33.2 |
| Incremental deferred tax liabilities |  |
|  |  |
| Intangible assets | $4,222.1$ |
| Book value of target intangible assets | $150.0 \%$ |
| \% Write-up | 6,333 |
| Asset write-up | 20 years |
| Useful life | 316.6575 |
| Incremental amortization expense | $1,361.6$ |
| Incremental deferred tax liabilities |  |
| Purchase Price Allocation | $13,434.0$ |
| Target assets - book value | 154.5 |
| Plus: PP\&E write ups | 6,333 |
| Plus: Intangible asset write ups | $(3,990.7)$ |
| Less: Write off of target goodwill | $723.2)$ |
| Less: Write off of target deferred tax assets | $\mathbf{1 5 , 2 0 7 . 8}$ |
| Target assets - fair market value | $9,962.5$ |
| Target liabilities - book value | 0.0 |
| Less: Write off of target deferred tax liabilities | $1,394.9$ |
| Plus: New deferred tax liabilities created | $\mathbf{1 1 , 3 5 7 . 4}$ |
| Target liabilities - fair market value | $3,850.44$ |
|  | $\$ 6,546.63$ |
| Target net book value - fair market value | $\mathbf{2 , 6 9 6 . 2}$ |
| Offer value |  |
| Goodwill created in transaction |  |

(\$ in millions)

| Pro Forma Balance Sheet |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Standalone |  | Adjustments |  | Pro Forma |
|  | $\begin{gathered} \hline \text { Acquirer } \\ \text { EL } \\ 12 / 31 / 21 \\ \hline \end{gathered}$ | Target COTY <br> 12/31/21 | Increase | (Decrease) |  |
| Cash and equivalents | 4,603.0 | 562.5 |  | $(1,871)$ | 3,294.6 |
| Accounts receivable | 2,079.0 | 506.8 |  |  | 2,585.8 |
| Inventory | 2,612.0 | 589.0 |  |  | 3,201.0 |
| Deferred tax assets (current and long term) | 0.0 | 723.2 |  | (723.2) | 0.0 |
| Other current assets | 661.0 | 520.1 |  |  | 1,181.1 |
| PP\&E | 4,553.0 | 772.7 | 154.5 |  | 5,480.2 |
| Intangible assets | 3,883.0 | 4,222.1 | 6,436.5 |  | 14,541.6 |
| Goodwill | 2,572.0 | 3,990.7 | 2,696.2 | $(3,990.7)$ | 5,268.2 |
| Other assets | 1,115.0 | 1,546.9 |  |  | 2,661.9 |
| Total assets | 22,078.0 | 13,434.0 |  |  | \$35,512.0 |
| Accounts payable | 1,639.0 | 1,394.3 |  |  | 3,033.3 |
| Accrued expenses \& def rev. (current \& non-current) | 3,851.0 | 1,327.1 |  |  | 5,178.1 |
| Revolver and current debt | 272.0 | 93.8 |  | (93.8) | 272.0 |
| Long term debt | 7,287.0 | 5,130.8 | 10,335.2 | $(5,130.8)$ | 17,622.2 |
| Convertible debt | 0.0 | 0.0 |  | 0.0 | 0.0 |
| Deferred tax liabilities | 0.0 | 776.7 | 1,394.9 | 0.0 | 2,171.6 |
| Other liabilities | 1,937.0 | 816.6 |  |  | 2,753.6 |
| Preferred stock | 0.0 | 142.4 |  |  | 142.4 |
| Noncontrolling interests | 874.0 | 280.8 |  |  | 1,154.8 |
| Shareholders' equity | 6,218.0 | 3,471.5 | 0 | $(3,602.4)$ | 6,087.1 |
| Total liabilities + shareholder equity | \$22,078.0 | \$13,434.0 |  |  | \$35,512.0 |
| Balance check. | Balanced | Balanced |  |  | Balanced |
| Credit statistics | EL | COTY |  |  | Pro Forma |
| Total debt | 7,559.0 | 5,224.6 |  |  | 17,894.2 |
| + Noncontrolling interests | 874.0 | 280.8 |  |  | 1,154.8 |
| + Preferred stock | 0.0 | 142.4 |  |  | 142.4 |
| - Cash \& equivalents | $(4,603.0)$ | (562.5) |  |  | $(3,294.6)$ |
| Net debt | 3,830.0 | 5,085.3 |  |  | 15,896.8 |
| Equity value (share price x shares out.) | 83,442.7 | 6,546.6 |  |  | 83,442.7 |
| Enterprise value | 87,272.7 | 11,631.9 |  |  | 99,339.5 |
| EBITDA for the calendar year ending 2022 | 4,736.0 | 952.0 |  |  | 5,688.0 |
| Gross Debt / EBITDA | 1.8x | 5.9x |  |  | 3.4 x |
| Enterprise value / EBITDA | 18.4x | 12.2x |  |  | 17.5x |
| Debt / Equity | 10.1\% | 86.3\% |  |  | 23.0\% |

## (\$ in millions)

| Accretion/Dilution Analysis |  |  |  |
| :---: | :---: | :---: | :---: |
| EPS Accounting: GAAP EPS | FY 2022 | FY 2023 | FY 2024 |
| Acquirer | 6/30/2022 | 6/30/2023 | 6/30/2024 |
| Net income | 2964.63 | 3547.60 | 4030.73 |
| GAAP EPS | 8.21 | 9.82 | 11.16 |
| Diluted shares outstanding (weighted avg.) | 361.22 | 361.22 | 361.22 |
| Target |  |  |  |
| Net income | 212.65 | 343.57 | 493.16 |
| GAAP EPS | 0.25 | 0.40 | 0.57 |
| Diluted shares outstanding (weighted avg.) | 864.58 | 864.58 | 864.58 |
| Transaction related expenses/income ${ }^{(1)}$ |  |  |  |
| Less: Interest expense from new deal debt | (204.4) | (204.4) | (204.4) |
| Less: Interest income on cash forgone | (18.7) | (18.7) | (18.7) |
| Plus: Synergies | 100.00 | 100.00 | 100.00 |
| Less: Incremental D\&A expense | (327.0) | (327.0) | (327.0) |
| Less: Financing fee amortization | (20.7) | (20.7) | (20.7) |
| Taxes (assumed at acquirer's rate) | 101.2 | 101.2 | 101.2 |
| Total after tax transaction related income / (expenses) | (369.5) | (369.5) | (369.5) |
|  |  |  |  |
| Pro Forma GAAP Net Income | 2807.74 | 3521.62 | 4154.35 |
| Pro Forma Shares Outstanding | 361.22 | 361.22 | 361.22 |
| Pro Forma GAAP EPS | \$7.77 | \$9.75 | \$11.50 |
| Acquirer standalone EPS | 8.21 | 9.82 | 11.16 |
| Accretion / Dilution per share | (\$0.43) | (\$0.07) | \$0.34 |
| Accretion / Dilution \% | (5.3\%) | (0.7\%) | 3.1\% |
| Additional pretax synergies required to breakeven | 129.1 | 21.4 | - |


| Sensitivity Analysis |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Accretion Dilution - Year 1 |  |  |  |  |  |
| Relevant assumptions | \% Stock | Offer price |  |  |  |
| Current offer price |  | \$7.50 | \$10.00 | \$12.50 | \$15.00 |
| \$7.57 | 100\% | (0.99) | (1.31) | (1.61) | (1.89) |
| Current \% stock | 75\% | (0.86) | (1.14) | (1.41) | (1.67) |
| 0.0\% | 50\% | (0.72) | (0.97) | (1.21) | (1.44) |
| \% Cash consideration financed with debt | 25\% | (0.58) | (0.78) | (0.99) | (1.19) |
| 75.0\% | 0\% | (0.43) | (0.59) | (0.75) | (0.91) |
| Accretion Dilution - Year 2 |  |  |  |  |  |
| Relevant assumptions | \% Stock |  | Offer |  |  |
| Current offer price |  | \$7.50 | \$10.00 | \$12.50 | \$15.00 |
| \$7.57 | 100\% | (0.77) | (1.13) | (1.47) | (1.80) |
| Current \% stock | 75\% | (0.60) | (0.92) | (1.22) | (1.52) |
| 100.0\% | 50\% | (0.43) | (0.70) | (0.96) | (1.22) |
| \% Cash consideration financed with debt | 25\% | (0.25) | (0.47) | (0.69) | (0.90) |
| 25.0\% | 0\% | (0.07) | (0.23) | (0.39) | (0.55) |
| Accretion Dilution - Year 3 |  |  |  |  |  |
| Relevant assumptions | \% Stock |  | Offer |  |  |
| Current offer price |  | \$7.50 | \$10.00 | \$12.50 | \$15.00 |
| \$7.57 | 100\% | (0.48) | (0.88) | (1.26) | (1.62) |
| Current \% stock | 75\% | (0.29) | (0.63) | (0.97) | (1.29) |
| 0.0\% | 50\% | (0.08) | (0.37) | (0.66) | (0.93) |
| \% Cash consideration financed with debt | 25\% | 0.13 | (0.10) | (0.33) | (0.55) |
| 75.0\% | 0\% | 0.35 | 0.19 | 0.02 | (0.14) |


| Accretion Dilution - Year 1 |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Relevant assumptions | \% Stock | \% Cash consideration financed with debt |  |  |  |
| Current offer price |  | 0\% | 25\% | 50\% | 100\% |
| \$7.57 | 100\% | (0.68) | (0.79) | (0.89) | (1.11) |
| Current \% stock | 75\% | (0.54) | (0.65) | (0.76) | (0.97) |
| 0.0\% | 50\% | (0.40) | (0.51) | (0.62) | (0.84) |
| \% Cash consideration financed with debt | 25\% | (0.25) | (0.36) | (0.47) | (0.70) |
| 75.0\% | 0\% | (0.09) | (0.21) | (0.32) | (0.55) |
| Debt / LTM EBITDA multiple |  |  |  |  |  |
| Relevant assumptions | \% Stock |  | Offer |  |  |
| Current offer price |  | \$7.50 | \$10.00 | \$12.50 | \$15.00 |
| \$7.57 | 100\% | 3.37 | 3.65 | 3.94 | 4.22 |
| Current \% stock | 75\% | 3.37 | 3.65 | 3.94 | 4.22 |
| 0.0\% | 50\% | 3.37 | 3.65 | 3.94 | 4.22 |
| \% Cash consideration financed with debt | 25\% | 3.37 | 3.65 | 3.94 | 4.22 |
| 75.0\% | 0\% | 3.37 | 3.65 | 3.94 | 4.22 |

(\$ in millions, except per share items)

| Market value | The Estée Lauder Companies, Inc. | COTY INC. | Pro Forma |
| :--- | ---: | ---: | ---: |
| Price per share | $\$ 231.00$ | $\$ 6.31$ |  |
| Diluted shares outstanding | 361.22 | 864.6 |  |
| Equity value | $83,422.7$ | $5,455.5$ |  |
| Net debt | $3,830.0$ | $5,085.3$ |  |
| Enterprise value | $87,272.7$ | $10,540.8$ |  |
| Contribution \$ in MM |  |  |  |
| Revenue (FY+1) | $18,566.8$ | $5,288.5$ | $23,855.3$ |
| EBITDA (FY+1) | $4,644.6$ | 931.0 | $5,575.6$ |
| Net Income (FY+1) | $2,964.6$ | 212.7 | $3,177.3$ |
| Contribution \% |  |  |  |
| Revenue (FY+1) | $77.8 \%$ | $22.2 \%$ | $100 \%$ |
| EBITDA (FY+1) | $83.3 \%$ | $16.7 \%$ | $100 \%$ |
| Net Income (FY+1) | $93.3 \%$ | $6.7 \%$ | $100 \%$ |
| Enterprise Value | $89.2 \%$ | $10.8 \%$ | $100 \%$ |
| Multiples |  |  |  |
| Revenue (FY+1) | 4.70 x | 1.99 x |  |
| EBITDA (FY+1) | 18.79 x | 11.32 x | 4.10 x |
| Net Income (FY+1) | 28.15 x | 25.65 x | 17.54 x |

Contribution Analysis


■The Estée Lauder Companies, Inc. ■ COTY INC.


## Risks

- Rising cases of COVID-19 or reimplemented lockdowns or restrictions may significantly affect the recovery and growth of sales for Estée Lauder and COTY, as many of their products are luxury goods or linked with travel and leisure activities
- Since COTY sells more prestige beauty products than mass, Estée Lauder would become more exposed to this risk
- The merger adds $\sim \$ 5.20$ bn in long-term debt for Estée Lauder and heavily affects their cash balance, affecting overall liquidity
- If the acquirer does not capitalize off the innovation and product synergies from the deal, they may fall behind competitors
- If Estée Lauder continues to have management issues, it can affect its own reputation and affect COTY's product demand
- Supply chain issues and costs may affect Company margins and top-line growth if COTY's COGS do not go down if acquired - COTY's COGS were $\sim 31.00 \%$ of revenue in FY2021, compared to $\sim 19.00 \%$ for Estée Lauder, a more established firm


## Bull Case

- Estée Lauder uses COTY's luxury personal product portfolio to rapidly grow sales and reach new audiences
- Innovation for beauty care grows due to synergies from the merger and creates successful personal products
- COTY's COGS decrease dramatically from the acquisition to improve profits


## Base Case

- Estée Lauder takes advantage of COTY's luxury personal product portfolio to grow sales and reach new markets
- The merger spurs new innovation for both companies and creates new products due to expected firm synergies
- COTY's COGS significantly decrease from the acquisition to increase overall bottom lines


## Bear Case

- Estée Lauder fails to take advantage of COTY's product portfolio to grow sales and reach new demographics
- The merger does not influence new or successful innovations in beauty care for the Company and synergies are not realized
- COTY's COGS remain at similar levels prior to the merger, affecting bottom lines

